These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21362228)

  • 1. [Prognostic significance of serial determinations of lactate dehydrogenase in follow-up for patients with myelodysplastic syndrome].
    Zhang YQ; Dai HB; Wang JH; Li XY; Dai SM; Yao DD; Ma LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):85-9. PubMed ID: 21362228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
    Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of laboratory indexes with prognosis in patients with myelodysplastic syndrome].
    Li WW; Li Y; Wang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):116-9. PubMed ID: 22391179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes.
    Wimazal F; Sperr WR; Kundi M; Vales A; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Valent P
    Ann Oncol; 2008 May; 19(5):970-6. PubMed ID: 18272915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes.
    Wimazal F; Sperr WR; Kundi M; Meidlinger P; Fonatsch C; Jordan JH; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Lechner K; Valent P
    Leuk Res; 2001 Apr; 25(4):287-94. PubMed ID: 11248325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
    Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
    Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
    Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
    Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A preliminary study of prognostic value of thrombocytopenia in patients with primary myelodysplastic syndromes].
    Chen YD; Xu ZF; Cui R; Wang JY; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Zhang Y; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):532-5. PubMed ID: 22967412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome].
    Aul C; Germing U; Gattermann N; Söhngen D; Heyll A
    Dtsch Med Wochenschr; 1996 Sep; 121(37):1113-8. PubMed ID: 8925725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement and clinical significance of serum TPO and LDH levels in patients with myelodysplastic syndrome and acute leukemia.
    Wu YX; Wang HY; Wang W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):671-4. PubMed ID: 20561425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].
    Su T; Zhang PH; Xu ZF; Chen HS; Qin TJ; Zhang Y; Zhang HL; Fan LW; Pan LJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):378-82. PubMed ID: 22781796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
    Tong WG; Quintás-Cardama A; Kadia T; Borthakur G; Jabbour E; Ravandi F; Faderl S; Wierda W; Pierce S; Shan J; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
    Cancer; 2012 Sep; 118(18):4462-70. PubMed ID: 22252728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score.
    Aul C; Gattermann N; Germing U; Runde V; Heyll A; Schneider W
    Leukemia; 1994 Nov; 8(11):1906-13. PubMed ID: 7967735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
    Wimazal F; Germing U; Kundi M; Noesslinger T; Blum S; Geissler P; Baumgartner C; Pfeilstoecker M; Valent P; Sperr WR
    Cancer; 2010 May; 116(10):2372-81. PubMed ID: 20209617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.